Semaglutide vs Retatrutide vs Tirzepatide: GLP-1 Comparison | PSPeptides

Semaglutide vs. Retatrutide vs. Tirzepatide: Comparing GLP-1 Research Peptides

The GLP-1 receptor agonist class has expanded rapidly, and researchers now have three distinct compounds to study — each targeting a different number of metabolic receptors with different efficacy profiles. Semaglutide (single agonist), tirzepatide (dual agonist), and retatrutide (triple agonist) represent three generations of incretin-based research, each building on the last.

This guide compares all three compounds across receptor targets, published clinical data, mechanisms, and practical research considerations.

The Core Difference: Receptor Targets

The fundamental distinction between these three peptides is how many metabolic receptors they engage:

Semaglutide activates only the GLP-1 receptor. This suppresses appetite, delays gastric emptying, and promotes glucose-dependent insulin secretion. It’s the most extensively studied compound in this class, with FDA approval under the brand names Ozempic (diabetes) and Wegovy (weight management).

Tirzepatide activates both the GLP-1 and GIP receptors. The addition of GIP receptor agonism enhances insulin secretion and appears to influence lipid metabolism and adipose tissue function beyond what GLP-1 alone achieves. It’s FDA-approved as Mounjaro (diabetes) and Zepbound (weight management).

Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon receptor agonism is the critical differentiator — it stimulates lipolysis, increases fatty acid oxidation, elevates basal energy expenditure, and promotes thermogenesis. This means retatrutide doesn’t just reduce energy intake (like semaglutide and tirzepatide) but also actively increases energy expenditure. Retatrutide is currently in Phase 3 clinical trials and is not FDA-approved.

Head-to-Head Comparison

Why Retatrutide’s Triple Agonism Matters for Research

The addition of glucagon receptor agonism creates a fundamentally different metabolic profile. Semaglutide and tirzepatide primarily reduce energy intake — they make subjects eat less through appetite suppression and delayed gastric emptying. Retatrutide does this too, but adds an energy expenditure component through glucagon receptor activation.

This dual-action approach (reduced intake + increased expenditure) may explain two notable findings from retatrutide clinical trials: greater magnitude of weight reduction achieved in shorter timeframes (24.2% at 48 weeks vs. tirzepatide’s 22.5% at 72 weeks), and no observed weight-loss plateau at the end of the study period — participants were still losing weight when the trials ended, suggesting the full efficacy potential hadn’t been reached.

For researchers studying metabolic pathways, retatrutide offers the ability to investigate three-receptor coordination in a single molecule, something that cannot be replicated by combining separate single-target compounds.

Published Clinical Data

Semaglutide (STEP Trials)

The STEP clinical trial program established semaglutide as the first incretin-based therapy to demonstrate clinically meaningful weight reduction. At the 2.4mg weekly dose, participants achieved approximately 16% mean weight loss over 68 weeks. Semaglutide also demonstrated cardiovascular benefit, leading to expanded indications.

Tirzepatide (SURMOUNT Trials)

Tirzepatide’s dual-agonist approach produced greater weight reduction than semaglutide in head-to-head comparisons. At the highest studied dose (15mg weekly), participants achieved approximately 22.5% mean weight loss over 72 weeks. The addition of GIP receptor agonism appeared to enhance efficacy beyond what GLP-1 alone could achieve.

Retatrutide (Phase 2, NEJM 2023)

Published in The New England Journal of Medicine, the Phase 2 trial enrolled 338 adults and demonstrated dose-dependent weight reduction. At the 12mg dose, participants achieved 24.2% mean weight loss (approximately 57.8 lbs) at 48 weeks. Over 90% of participants in the 12mg group lost at least 10% of baseline weight, and approximately 25% lost 30% or more. Cardiometabolic improvements included reductions in blood pressure, triglycerides, LDL-cholesterol, and HbA1c.

Retatrutide Phase 3 (TRIUMPH-4)

The Phase 3 TRIUMPH-4 trial reported average weight loss of approximately 71.2 lbs (32.3 kg) with the 12mg dose over 68 weeks, with concurrent improvements in knee osteoarthritis pain scores.

Safety Comparison

All three compounds share a similar gastrointestinal side effect profile — nausea, diarrhea, vomiting, and constipation are the most commonly reported adverse events, occurring more frequently at higher doses. This is consistent across the incretin class and is generally dose-dependent and transient.

Retatrutide additionally reported cutaneous hyperesthesia (skin sensitivity) in approximately 7% of participants versus 1% for placebo — an effect not commonly seen with semaglutide or tirzepatide. No cases of clinically significant hypoglycemia, medullary thyroid cancer, or C-cell hyperplasia were reported in any retatrutide trials.

Research Availability

Semaglutide and tirzepatide are FDA-approved pharmaceuticals available by prescription. They are also subject to active intellectual property enforcement by Novo Nordisk and Eli Lilly respectively, which has driven enforcement actions against grey-market suppliers.

Retatrutide is not yet FDA-approved and is currently in Phase 3 clinical trials. It is available for laboratory research purposes from qualified peptide suppliers.

PSPeptides offers research-grade Retatrutide at 99%+ verified purity, manufactured in the US with independent third-party testing:

Buy Retatrutide — Available in 5mg, 10mg, 20mg, 30mg →

Frequently Asked Questions

Which compound produces the most weight loss in research?

Based on published clinical trial data, retatrutide has demonstrated the greatest magnitude of weight reduction (24.2% at 48 weeks), surpassing tirzepatide (22.5% at 72 weeks) and semaglutide (16% at 68 weeks) — and in a shorter timeframe. Participants had not yet reached a weight plateau, suggesting additional efficacy beyond what was measured.

Why does retatrutide work differently than semaglutide?

Semaglutide targets one receptor (GLP-1) that primarily reduces appetite. Retatrutide targets three receptors, adding GIP (enhanced insulin response) and glucagon (increased energy expenditure and fat oxidation). The glucagon component is the key differentiator — it activates an energy-burning pathway that semaglutide doesn’t touch.

Is retatrutide available for purchase?

Retatrutide is available for laboratory research purposes. It is not FDA-approved and is not available in pharmacies. PSPeptides carries research-grade Retatrutide at 99%+ verified purity.

References

1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526.
2. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab. 2022;34(9):1234-1247.e9.
3. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(4):327-340.
4. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.

This content is for educational and research purposes only. All products are intended for laboratory research use only. Not for human consumption.

PSPeptides — US Made & Shipped | Third-Party Tested | 99%+ Purity | Same-Day Shipping